<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39331891</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>103</Volume><Issue>39</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>27</Day></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Pharmacological targets and validation of remdesivir for the treatment of COVID-19-associated pulmonary fibrosis: A network-based pharmacology and bioinformatics study.</ArticleTitle><Pagination><StartPage>e39062</StartPage><MedlinePgn>e39062</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e39062</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000039062</ELocationID><Abstract><AbstractText>The objective of this study was to employ bioinformatics and network pharmacology methodologies to investigate the targets and molecular mechanisms of remdesivir in the treatment of coronavirus disease 2019 (COVID-19)-associated pulmonary fibrosis (PF). Several open-source databases were utilized to confirm the shared targets of remdesivir, COVID-19, and PF. Following this, a comprehensive analysis incorporating function enrichment, protein-protein interaction (PPI), transcription factor (TF), and molecular docking was conducted to investigate the potential mechanisms underlying the effectiveness of remdesivir in the treatment of COVID-19-associated PF. The initial validation of these findings was performed using publicly available histological and single-cell sequencing databases. The functional enrichment analysis revealed a strong association between remdesivir and viral defense, inflammatory response, and immune response. The key pathways identified in the study were transforming growth factor (TGF-β), PI3K-Akt, mTOR, MAPK, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor resistance, HIF-1, and Toll-like receptor signaling pathways. Additionally, the PPI analysis demonstrated the network relationships of 13 important targets, while the TF analysis provided valuable insights into the regulatory networks of these targets. Among the identified TFs, RELA was found to be the most significant. To validate our findings, we utilized publicly available histological and single-cell sequencing databases, successfully confirming the involvement of 8 key targets, including AKT1, EGFR, RHOA, MAPK1, PIK3R1, MAPK8, MAPK14, and MTOR. Furthermore, molecular docking studies were conducted to assess the interaction between remdesivir and the identified key targets, thus confirming its effective targeting effects. Remdesivir has the potential to exert antiviral, anti-inflammatory, and immunomodulatory effects in the context of COVID-19-associated PF.</AbstractText><CopyrightInformation>Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Xueping</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, The First People's Hospital of Hangzhou Lin'an District, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Liping</ForeName><Initials>L</Initials><Identifier Source="ORCID">0009-0007-2519-8454</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Drug Clinical Risk and Personalized Medication Evaluation, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>3QKI37EEHE</RegistryNumber><NameOfSubstance UI="C000606551">remdesivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>415SHH325A</RegistryNumber><NameOfSubstance UI="D000249">Adenosine Monophosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber><NameOfSubstance UI="D000409">Alanine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000249" MajorTopicYN="Y">Adenosine Monophosphate</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000409" MajorTopicYN="Y">Alanine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="Y">Computational Biology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062105" MajorTopicYN="Y">Molecular Docking Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011658" MajorTopicYN="Y">Pulmonary Fibrosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000091484" MajorTopicYN="N">Network Pharmacology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060066" MajorTopicYN="N">Protein Interaction Maps</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>18</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>18</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>16</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39331891</ArticleId><ArticleId IdType="pmc">PMC11441881</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000039062</ArticleId><ArticleId IdType="pii">00005792-202409270-00034</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chen G, Wu D, Guo W, et al. . Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130:2620–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7190990</ArticleId><ArticleId IdType="pubmed">32217835</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnham EL, Janssen WJ, Riches DW, et al. . The fibroproliferative response in acute respiratory distress syndrome: mechanisms and clinical significance. Eur Respir J. 2014;43:276–85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4015132</ArticleId><ArticleId IdType="pubmed">23520315</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan Y, Guan H, Zhou S, et al. . Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China. Eur Radiol. 2020;30:3306–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7087663</ArticleId><ArticleId IdType="pubmed">32055945</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou S, Wang Y, Zhu T, et al. . CT features of coronavirus disease 2019 (COVID-19) pneumonia in 62 patients in Wuhan, China. AJR Am J Roentgenol. 2020;214:1287–94.</Citation><ArticleIdList><ArticleId IdType="pubmed">32134681</ArticleId></ArticleIdList></Reference><Reference><Citation>Polak SB, Van Gool IC, Cohen D, et al. . A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression. Mod Pathol. 2020;33:2128–38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7306927</ArticleId><ArticleId IdType="pubmed">32572155</ArticleId></ArticleIdList></Reference><Reference><Citation>Spagnolo P, Kropski JA, Jones MG, et al. . Idiopathic pulmonary fibrosis: disease mechanisms and drug development. Pharmacol Ther. 2021;222:107798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8142468</ArticleId><ArticleId IdType="pubmed">33359599</ArticleId></ArticleIdList></Reference><Reference><Citation>Selman M, Pardo A. Idiopathic pulmonary fibrosis: an epithelial/fibroblastic cross-talk disorder. Respir Res. 2002;3:3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC64814</ArticleId><ArticleId IdType="pubmed">11806838</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghu G, Remy-Jardin M, Richeldi L, et al. . Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205:e18–47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9851481</ArticleId><ArticleId IdType="pubmed">35486072</ArticleId></ArticleIdList></Reference><Reference><Citation>Beigel JH, Nam HH, Adams PL, et al. . Advances in respiratory virus therapeutics - a meeting report from the 6th isirv Antiviral Group conference. Antiviral Res. 2019;167:45–67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7132446</ArticleId><ArticleId IdType="pubmed">30974127</ArticleId></ArticleIdList></Reference><Reference><Citation>Beigel JH, Tomashek KM, Dodd LE, et al. . Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020;383:1813–26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7262788</ArticleId><ArticleId IdType="pubmed">32445440</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali K, Azher T, Baqi M, et al. . Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. CMAJ. 2022;194:E242–51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8863204</ArticleId><ArticleId IdType="pubmed">35045989</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Liu R, Cui Y, et al. . Protective effect of remdesivir against pulmonary fibrosis in mice. Front Pharmacol. 2021;12:692346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8427522</ArticleId><ArticleId IdType="pubmed">34512328</ArticleId></ArticleIdList></Reference><Reference><Citation>赵雪萍 杨莉萍. COVID-19引发肺纤维化的案例报道汇总分析. . 中国医院药学杂志. 2023;43:663–8.</Citation></Reference><Reference><Citation>Bader GD, Hogue CW. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinf. 2003;4:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC149346</ArticleId><ArticleId IdType="pubmed">12525261</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Z, Kui Z, Ping Z. Reviews and prospectives of signaling pathway analysis in idiopathic pulmonary fibrosis. Autoimmun Rev. 2014;13:1020–5.</Citation><ArticleIdList><ArticleId IdType="pubmed">25182202</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito S, Zhuang Y, Shan B, et al. . Tubastatin ameliorates pulmonary fibrosis by targeting the TGFbeta-PI3K-Akt pathway. PLoS One. 2017;12:e0186615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5646855</ArticleId><ArticleId IdType="pubmed">29045477</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto S, Gon Y, Takeshita I, et al. . Transforming growth Factor-beta1 induces phenotypic modulation of human lung fibroblasts to myofibroblast through a c-Jun-NH2-terminal kinase-dependent pathway. Am J Respir Crit Care Med. 2001;163:152–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">11208641</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y, Azad N, Wang L, et al. . Phosphatidylinositol-3-kinase/akt regulates bleomycin-induced fibroblast proliferation and collagen production. Am J Respir Cell Mol Biol. 2010;42:432–41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2848736</ArticleId><ArticleId IdType="pubmed">19520917</ArticleId></ArticleIdList></Reference><Reference><Citation>Vignot S, Faivre S, Aguirre D, et al. . mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol. 2005;16:525–37.</Citation><ArticleIdList><ArticleId IdType="pubmed">15728109</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang A, Zou Y, Xu Q, et al. . Investigation of the pharmacological effect and mechanism of jinbei oral liquid in the treatment of idiopathic pulmonary fibrosis using network pharmacology and experimental validation. Front Pharmacol. 2022;13:919388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9240387</ArticleId><ArticleId IdType="pubmed">35784749</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouhaddou M, Memon D, Meyer B, et al. . The global phosphorylation landscape of SARS-CoV-2 infection. Cell. 2020;182:685–712.e19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7321036</ArticleId><ArticleId IdType="pubmed">32645325</ArticleId></ArticleIdList></Reference><Reference><Citation>Soucheray M, Capelletti M, Pulido I, et al. . Intratumoral heterogeneity in EGFR-Mutant NSCLC results in divergent resistance mechanisms in response to EGFR tyrosine kinase inhibition. Cancer Res. 2015;75:4372–83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4548796</ArticleId><ArticleId IdType="pubmed">26282169</ArticleId></ArticleIdList></Reference><Reference><Citation>Osawa M, Kudoh S, Sakai F, et al. . Clinical features and risk factors of panitumumab-induced interstitial lung disease: a postmarketing all-case surveillance study. Int J Clin Oncol. 2015;20:1063–71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4666285</ArticleId><ArticleId IdType="pubmed">25967287</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian M, Liu W, Li X, et al. . HIF-1alpha promotes SARS-CoV-2 infection and aggravates inflammatory responses to COVID-19. Signal Transduct Target Ther. 2021;6:308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8371950</ArticleId><ArticleId IdType="pubmed">34408131</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng T, Poth JM, Karmouty-Quintana H, et al. . Hypoxia-induced deoxycytidine kinase contributes to epithelial proliferation in pulmonary fibrosis. Am J Respir Crit Care Med. 2014;190:1402–12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4299646</ArticleId><ArticleId IdType="pubmed">25358054</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Hu Y, Deng WW, et al. . Negative regulation of Toll-like receptor signaling pathway. Microbes Infect. 2009;11:321–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">19146978</ArticleId></ArticleIdList></Reference><Reference><Citation>Upagupta C, Shimbori C, Alsilmi R, et al. . Matrix abnormalities in pulmonary fibrosis. Eur Respir Rev. 2018;27:180033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9489108</ArticleId><ArticleId IdType="pubmed">29950306</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardo A, Selman M, Kaminski N. Approaching the degradome in idiopathic pulmonary fibrosis. Int J Biochem Cell Biol. 2008;40:1141–55.</Citation><ArticleIdList><ArticleId IdType="pubmed">18207447</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulkarni T, O’Reilly P, Antony VB, et al. . Matrix remodeling in pulmonary fibrosis and emphysema. Am J Respir Cell Mol Biol. 2016;54:751–60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4942216</ArticleId><ArticleId IdType="pubmed">26741177</ArticleId></ArticleIdList></Reference><Reference><Citation>Salton F, Volpe MC, Confalonieri M. Epithelial(-)mesenchymal transition in the pathogenesis of idiopathic pulmonary fibrosis. Medicina (Kaunas). 2019;55:83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6524028</ArticleId><ArticleId IdType="pubmed">30925805</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng D, Chen XQ, Qiu H, et al. . The role of infection in acute exacerbation of idiopathic pulmonary fibrosis. Mediators Inflamm. 2019;2019:5160694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6335849</ArticleId><ArticleId IdType="pubmed">30718973</ArticleId></ArticleIdList></Reference><Reference><Citation>Huie TJ, Olson AL, Cosgrove GP, et al. . A detailed evaluation of acute respiratory decline in patients with fibrotic lung disease: aetiology and outcomes. Respirology. 2010;15:909–17.</Citation><ArticleIdList><ArticleId IdType="pubmed">20546190</ArticleId></ArticleIdList></Reference><Reference><Citation>Alharbi KS, Fuloria NK, Fuloria S, et al. . Nuclear factor-kappa B and its role in inflammatory lung disease. Chem Biol Interact. 2021;345:109568.</Citation><ArticleIdList><ArticleId IdType="pubmed">34181887</ArticleId></ArticleIdList></Reference><Reference><Citation>Rameshwar P, Narayanan R, Qian J, et al. . NF-kappa B as a central mediator in the induction of TGF-beta in monocytes from patients with idiopathic myelofibrosis: an inflammatory response beyond the realm of homeostasis. J Immunol. 2000;165:2271–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">10925316</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Wang J, Wang J, et al. . HMGB1 induces lung fibroblast to myofibroblast differentiation through NF‑kappaB‑mediated TGF‑beta1 release. Mol Med Rep. 2017;15:3062–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5428737</ArticleId><ArticleId IdType="pubmed">28339089</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaffar J, Glaspole I, Symons K, et al. . Inhibition of NF-kappaB by ACT001 reduces fibroblast activity in idiopathic pulmonary fibrosis. Biomed Pharmacother. 2021;138:111471.</Citation><ArticleIdList><ArticleId IdType="pubmed">33730605</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez IE, Eickelberg O. New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis. Lancet. 2012;380:680–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">22901889</ArticleId></ArticleIdList></Reference><Reference><Citation>Baum J, Duffy HS. Fibroblasts and myofibroblasts: what are we talking about? J Cardiovasc Pharmacol. 2011;57:376–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3077448</ArticleId><ArticleId IdType="pubmed">21297493</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson-Casey JL, Deshane JS, Ryan AJ, et al. . Macrophage Akt1 kinase-mediated mitophagy modulates apoptosis resistance and pulmonary fibrosis. Immunity. 2016;44:582–96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4794358</ArticleId><ArticleId IdType="pubmed">26921108</ArticleId></ArticleIdList></Reference><Reference><Citation>Revathidevi S, Munirajan AK. Akt in cancer: Mediator and more. Semin Cancer Biol. 2019;59:80–91.</Citation><ArticleIdList><ArticleId IdType="pubmed">31173856</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev. 1999;13:2905–27.</Citation><ArticleIdList><ArticleId IdType="pubmed">10579998</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia QD, Xun Y, Lu JL, et al. . Network pharmacology and molecular docking analyses on Lianhua Qingwen capsule indicate Akt1 is a potential target to treat and prevent COVID-19. Cell Prolif. 2020;53:e12949.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7705900</ArticleId><ArticleId IdType="pubmed">33140889</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Wang D, Li Z, et al. . Pan-cancer analysis on the role of PIK3R1 and PIK3R2 in human tumors. Sci Rep. 2022;12:5924.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8993854</ArticleId><ArticleId IdType="pubmed">35395865</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu HS, Liu CC, Lin JH, et al. . Involvement of ER stress, PI3K/AKT activation, and lung fibroblast proliferation in bleomycin-induced pulmonary fibrosis. Sci Rep. 2017;7:14272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5660192</ArticleId><ArticleId IdType="pubmed">29079731</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkins PT, Stephens LR. PI3K signalling in inflammation. Biochim Biophys Acta. 2015;1851:882–97.</Citation><ArticleIdList><ArticleId IdType="pubmed">25514767</ArticleId></ArticleIdList></Reference><Reference><Citation>Margaria JP, Moretta L, Alves-Filho JC, et al. . PI3K signaling in mechanisms and treatments of pulmonary fibrosis following sepsis and acute lung injury. Biomedicines. 2022;10:756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9028704</ArticleId><ArticleId IdType="pubmed">35453505</ArticleId></ArticleIdList></Reference><Reference><Citation>Vagapova ER, Lebedev TD, Prassolov VS. Viral fibrotic scoring and drug screen based on MAPK activity uncovers EGFR as a key regulator of COVID-19 fibrosis. Sci Rep. 2021;11:11234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8160348</ArticleId><ArticleId IdType="pubmed">34045585</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts KL, Cottrell E, Hoban PR, et al. . RhoA signaling modulates cyclin D1 expression in human lung fibroblasts; implications for idiopathic pulmonary fibrosis. Respir Res. 2006;7:88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1513217</ArticleId><ArticleId IdType="pubmed">16776827</ArticleId></ArticleIdList></Reference><Reference><Citation>Knipe RS, Tager AM, Liao JK. The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis. Pharmacol Rev. 2015;67:103–17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4279074</ArticleId><ArticleId IdType="pubmed">25395505</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>